Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia

Muhammad Husnain, MD, University of Arizona, Arizona Cancer Center, Tucson, AZ, discusses the impact of pre-transplant molecular measurable residual disease (MMRD) and European Leukemianet (ELN) genetic classification in clinical outcomes for acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (alloHCT). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Muhammad Husnain

The role of CAR-T therapy in primary and secondary CNS lymphoma
1:57
The role of CAR-T therapy in primary and secondary CNS lymphoma
Muhammad Husnain • 24 Apr 2022
PTCy in MMUD HCT: the University of Miami experience
5:38
PTCy in MMUD HCT: the University of Miami experience
Muhammad Husnain • 17 Feb 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals